1. The controlled clinical trial - a model for the intricate
relationships between clinical medicine and drug research.- 1.1.
Introduction.- 1.2. The evolution of the controlled clinical trial
(CCT).- 1.3 The implementation of the controlled clinical trial in
drug research.- 1.4. Criticism of the classical view of the
controlled clinical trial.- 1.5. Conclusions.- 2. The architecture
of drug discovery.- 2.1. Introduction.- 1. The discovery process.-
2.2. Current views of drug discovery.- 2.2.1. Basic concepts in
drug discovery.- 2.2.2. Basic epistemologies in drug discovery.-
2.3. Scientific discovery from the viewpoint of cognitive science.-
2.4. The drug discovery process revisited.- 2. The representation
of knowledge about drugs and diseases.- 2.5. An epistemological
analysis of the concept of drug and disease profiles.- 2.5.1.
Introduction.- 2.5.2. The concept of drug profile.- 2.5.2.1..The
classification of drugs.- 2.5.2.2. Incursion of drug profiles into
disease profiles.- 2.5.2.3. The nature of drug characteristics.-
2.5.3. The concept of disease profile.- 2.5.3.1. Disease profiles
as pigeon holes of medical knowledge.- 2.5.3.2. The fundamental
basis of taxonomy in medicine.- 2.5.3.3. Convergent and divergent
forces in clinical taxonomy.- 2.5.3.4. The translation of everyday
medical language into the structure of profiles.- 2.5.4.
Conclusions.- 3. A set-theoretical model of drug discovery.- 2.6. A
definition of the concept of profile in terms of set theory.-
2.6.1. Introduction.- 2.6.2. The first aspect of a profile:
membership.- 2.6.3. The second aspect of the concept of profile:
values of the disease characteristics.- 2.6.4. The third aspect of
the concept of profile: ranking order of characteristics.- 2.6.5.
Conclusions.- 2.7. The drug discovery process - a set-theoretical
model.- 2.7.1. Introduction.- 2.7.2. A naive definition.- 2.7.3.
First adjustment of the naive defenition: structural and functional
characteristics of drugs.- 2.7.4. Second adjustment of the naive
defenition: disease characteristics.- 2.7.5. The improvement of
toxic effects of drugs: positive and negative aspects and their
judgment.- 2.7.6. Conclusions.- 3.Experimental and therapeutic
profiling in drug innovation: the early history of the beta
blockers.- 3.1. Introduction.- 3.2. Historical overview of the
development of the beta blockers.- 3.3. From Dale to Ahlquist: a
new methodology in pharmacology.- 3.4. Change in the concepts of
agonist and antagonist.- 3.5. Experimental and therapeutic
profiling in drug innovation.- 3.5.1. Cardiac arrhythmias.- 3.5.2.
Angina pectoris.- 3.6. Conclusions.- 4. Industrial research and
beta blockade.- 4.1. Introduction.- 4.2. Beta blocker research at
Imperial Chemical Industries (ICI).- 4.2.1. The early phase.-
4.2.2. The birth of pronethalol.- 4.2.3. The demise of
pronethalol.- 4.2.4. The development of propranolol.- 4.2.4.1. A
"clean" drug.- 4.2.4.2. The rapid expansion of a successful drug.-
4.2.4.3. Endangered drug.- 4.2.5. The development of practolol.-
4.2.5.1. Practolol: a tool in industrial research.- 4.2.5.2.
Selectivity in industrial and academic research.- 4.2.5.3. The
therapeutic interest.- 4.3. The beta blocker project of Eli Lilly
& Co..- 4.4. The beta blocker project of Mead Johnson.- 4.5.
The beta blocker project of AB Hassle.- 4.5.1. The early phase.-
4.5.2. Intrinsic sympathomimetic activity of alprenolol.- 4.5.3.
The profiling of alprenolol.- 4.5.4. Selective beta blockade.- 4.6.
The beta blocker project at CIBA.- 4.7. Conclusions.- 5. Verapamil:
dying drug or sleeping beauty?.- 5.1 Introduction.- 5.2 The early
history of verapamil.- 5.3 Verapamil: a coronary vasodilator?.- 5.4
Verapamil: a beta blocker?.- 5.5. Verapamil: a calcium antagonist!
- The elucidation of verapamil's mechanism of action by
Fleckenstein.- 5.6. Citation analysis of the concept of calcium
antagonism elaborated by Fleckenstein.- 5.7. The application of the
theory of drug and disease profiles.- 5.7.1. Changing views on the
General
| Imprint: |
Kluwer Academic Publishers
|
| Country of origin: |
United States |
| Series: |
Developments in Cardiovascular Medicine |
| Release date: |
December 1990 |
| First published: |
December 1990 |
| Authors: |
Rein Vos
|
| Dimensions: |
250mm (L) |
| Format: |
Hardcover
|
| Pages: |
384 |
| Edition: |
New |
| ISBN-13: |
978-0-7923-0968-0 |
| Categories: |
Books >
Medicine >
Clinical & internal medicine >
Cardiovascular medicine
|
| LSN: |
0-7923-0968-5 |
| Barcode: |
9780792309680 |
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
Welcome to Loot.co.za!
Sign in / Register |Wishlists & Gift Vouchers |Help | Advanced search
